Aligos Therapeutics, Inc.
ALGSNASDAQHealthcare● Active
$5.21
+$0.25(+5.04%)
Market Cap$32240637
P/E Ratio—
52W High$13.689
52W Low$4.8
Aligos Therapeutics, Inc. (ALGS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ALGS · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.19M | $3.94M | $15.53M | $13.91M | $4.36M |
| Cost of Revenue | $0.93M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $1.26M | $3.94M | $15.53M | $13.91M | $4.36M |
| Gross Margin %(computed) | 57.46% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $69.45M | $70.27M | $73.04M | $85.08M | $104.15M |
| G&A Expenses | $20.72M | $22.83M | $30.62M | $26.41M | $28.53M |
| Total Operating Expenses | $89.24M | $93.10M | $103.66M | $111.49M | $132.68M |
| Operating Income | ($87.98M) | ($89.15M) | ($88.13M) | ($97.58M) | ($128.32M) |
| Operating Margin %(computed) | — | — | -567.50% | -701.66% | — |
| Interest Income | $2.16M | $1.67M | $1.24M | $1.64M | $0.13M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($23.88M) | ($130.88M) | ($86.88M) | ($95.94M) | ($128.19M) |
| Income Tax Expense | $0.31M | $0.33M | $0.80M | $0.11M | $0.14M |
| Net Income | ($24.19M) | ($131.21M) | ($87.68M) | ($96.05M) | ($128.33M) |
| Net Margin %(computed) | — | — | -564.61% | -690.63% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.45 | $-20.94 | $-3.52 | $-2.25 | $-3.22 |
| Wtd Avg Shares | 9.88M | 6.26M | 24.87M | 42.70M | 39.86M |
| EBITDA | ($87.06M) | ($86.53M) | ($85.06M) | ($93.91M) | ($124.54M) |
| EBITDA Margin %(computed) | — | — | -547.74% | -675.24% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Aligos Therapeutics, Inc. data
About Aligos Therapeutics, Inc. (ALGS) Income Statement
Aligos Therapeutics, Inc. (ALGS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ALGS reported revenue of $0.00B, gross profit of $0.00B (gross margin 57.46%), and net income of ($0.02B) — a net profit margin of -1106.72%.
Frequently asked questions
ALGS · 4 questionsAligos Therapeutics, Inc. (ALGS) reported revenue of $0.00B for 2025, down 44.6% year-over-year.
ALGS revenueALGS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09